Table 4.
Adjusted odds ratios (aORs) between relative potency factor weighted summary disinfection by-product (DBP) exposures and obstructive genital defects.
| Weighted models: cases/controls | Weighted models: aOR (95% CI)a | Unweighted models: cases/controls | Unweighted models: aOR (95% CI)a | |
|---|---|---|---|---|
| DBP9 (BDCM>TBM>TCM>DBCM>HAA5)b | ||||
| Quintile 1 | 36/420 | 1.00 (ref) | 36/420 | 1.00 (Referent) |
| Quintile 2 | 47/419 | 1.38 (0.86, 2.22) | 47/420 | 1.39 (0.87, 2.25) |
| Quintile 3 | 45/419 | 1.24 (0.76, 2.01) | 45/420 | 1.32 (0.81, 2.14) |
| Quintile 4 | 35/419 | 1.06 (0.64, 1.73) | 35/421 | 1.02 (0.62, 1.69) |
| Quintile 5 | 47/417 | 1.33 (0.82, 2.15) | 47/419 | 1.39 (0.86, 2.25) |
| HAA9 (MBAA>BCAA>MCAA>DBAA>BDCAA>CDBAA>TCAA>TBAA>DCAA)c | ||||
| Quintile 1 | 36/413 | 1.00 (ref) | 36/413 | 1.00 (Referent) |
| Quintile 2 | 42/413 | 0.94 (0.56, 1.57) | 42/413 | 1.05 (0.58, 1.90) |
| Quintile 3 | 48/413 | 1.05 (0.63, 1.75) | 48/413 | 1.15 (0.59, 2.24) |
| Quintile 4 | 38/413 | 0.78 (0.45, 1.35) | 38/413 | 0.86 (0.41, 1.81) |
| Quintile 5 | 40/413 | 0.97 (0.57, 1.64) | 40/413 | 0.89 (0.40, 1.97) |
| HAA5 (MBAA>MCAA>DBAA>TCAA>DCAA)c | ||||
| Quintile 1 | 37/420 | 1.00 (ref) | 37/420 | 1.00 (Referent) |
| Quintile 2 | 46/420 | 1.35 (0.75, 2.42) | 46/420 | 1.10 (0.60, 2.02) |
| Quintile 3 | 46/420 | 0.73 (0.37, 1.44) | 46/420 | 1.06 (0.53, 2.10) |
| Quintile 4 | 40/420 | 0.94 (0.49, 1.81) | 40/420 | 0.90 (0.42, 1.92) |
| Quintile 5 | 41/420 | 0.87 (0.43, 1.76) | 41/420 | 0.86 (0.38, 1.91) |
| HAA3 (DBAA>TCAA>DCAA)c | ||||
| Quintile 1 | 33/416 | 1.00 (ref) | 37/416 | 1.00 (Referent) |
| Quintile 2 | 41/415 | 1.30 (0.71, 2.37) | 44/414 | 0.99 (0.54, 1.81) |
| Quintile 3 | 51/414 | 1.64 (0.85, 3.18) | 46/415 | 0.98 (0.48, 1.97) |
| Quintile 4 | 41/415 | 1.32 (0.63, 2.76) | 41/416 | 0.84 (0.39, 1.81) |
| Quintile 5 | 40/412 | 1.31 (0.62, 2.80) | 38/411 | 0.74 (0.32, 1.68) |
| TCAA+DCAA (TCAA>DCAA)c | ||||
| Quintile 1 | 33/415 | 1.00 (ref) | 38/416 | 1.00 (Referent) |
| Quintile 2 | 47/416 | 1.42 (0.75, 2.68) | 44/415 | 0.91 (0.50, 1.66) |
| Quintile 3 | 48/413 | 1.48 (0.70, 3.14) | 46/413 | 0.89 (0.44, 1.78) |
| Quintile 4 | 38/417 | 1.11 (0.49, 2.55) | 41/417 | 0.75 (0.35, 1.60) |
| Quintile 5 | 40/411 | 1.21 (0.51, 2.89) | 37/411 | 0.63 (0.28, 1.43) |
| THM4 (BDCM>TBM>TCM>DBCM)b | ||||
| Quintile 1 | 36/419 | 1.00 (ref) | 36/420 | 1.00 (Referent) |
| Quintile 2 | 45/419 | 1.35 (0.79, 2.31) | 43/420 | 1.32 (0.77, 2.27) |
| Quintile 3 | 44/417 | 1.33 (0.73, 2.42) | 46/420 | 1.43 (0.79, 2.58) |
| Quintile 4 | 41/419 | 1.25 (0.66, 2.34) | 37/420 | 1.18 (0.61, 2.28) |
| Quintile 5 | 44/418 | 1.29 (0.65, 2.56) | 48/420 | 1.54 (0.77, 3.09) |
| THM4+TCAA (BDCM>TBM>TCM>DBCM>TCAA)b | ||||
| Quintile 1 | 37/416 | 1.00 (ref) | 37/416 | 1.00 (Referent) |
| Quintile 2 | 43/415 | 1.66 (0.88, 3.13) | 43/416 | 1.26 (0.76, 2.08) |
| Quintile 3 | 47/415 | 1.50 (0.71, 3.17) | 47/415 | 1.35 (0.82, 2.22) |
| Quintile 4 | 31/413 | 1.45 (0.63, 3.32) | 31/416 | 0.88 (0.52, 1.51) |
| Quintile 5 | 48/413 | 1.39 (0.58, 3.31) | 48/415 | 1.29 (0.77, 2.16) |
| THMBr (BDCM>TBM>DBCM)b | ||||
| Tertile 1 | 53/697 | 1.00 (ref) | 53/699 | 1.00 (Referent) |
| Tertile 2 | 74/696 | 1.54 (1.00, 2.35) | 74/700 | 1.53 (1.00, 2.34) |
| Tertile 3 | 83/699 | 1.79 (1.18, 2.71) | 83/699 | 1.74 (1.15, 2.64) |
All models adjusted for maternal education (less than high school; high school graduate or GED; some college, associates, or technical degree; college degree), 2000 US Census tract income (continuous), number of prenatal care visits ( < 9; 9–11; 12; 13–15; >15), prenatal care payment source (private health insurance; Medicaid or CommonHealth; other including Medicare and Healthy Start), maternal smoking (yes; no), maternal age ( < 20; 20- < 35; ≥35). Further adjusted for DBP co-exposures: THM4 and THMBr models adjusted for HAA5; HAA9, HAA5, HAA3, and TCAA + DCAA models adjusted for THM4; THM4 + TCAA model adjusted for HAABr.
Relative potency factors weights based on BMD50 values from four studies: (1) Smith, et al., 1989; (2) Smith, et al., 1992; (3) Narotsky et al., 2011; (4) Narotsky et al., Submitted.
Relative potency factors weights based on BMD50 values from two studies: (1) Hunter, et al., 2006.; (2) Hunter et al., 1996.